
We are excited to announce the merger of Syner-G BioPharma Group and Sequoia Biotech Consulting, joining forces to deliver integrated solutions for life sciences.
Read the Press Release | Learn more about Sequoia
We are the world's leading CMC, Regulatory Affairs, and Medical Writing solutions provider for biopharma.



About Syner-g
Who We Are
What We Do
Pharmaceutical Development (CMC)
Pharmaceutical Development (CMC)
Regulatory Strategy & Submissions
Regulatory Strategy & Submissions
Functional Outsourcing Partnerships
Functional Outsourcing Partnerships
Medical Writing
Medical Writing
Quality & Compliance
Quality & Compliance
Our Capabilities
Why Syner-G?
Number of Years of Industry Experienced Sr. Consultants
Number of Employee and
Number of Ph.Ds World-wide
Number of INDs and IND Amendments Filed
Number of Post-Approval Major Supplements
Years As An Organization (aggregate across all Syner-G companies)
Assets Supported
Number of Agency Meetings



Careers
Latest Developments and Insights

Leveraging FDA Type A Meetings for Faster Drug Development
Navigating the FDA regulatory action process presents unique challenges, and unexpected setbacks can stall even the most promising development programs. FDA Type A Meetings provide sponsors with an opportunity to obtain regulatory advice and timely feedback on critical issues affecting…
Read Full Article

Pharmaceutical Drug Development Process: How New Medications Are Brought to Patients
Bringing a new drug to market is a long and highly regulated process designed to ensure safety, efficacy, and quality. The pharmaceutical drug development process moves through multiple stages—beginning with drug discovery, advancing through preclinical and clinical research, and ultimately…
Read Full Article

Breakthrough Therapy Designation: What It Is and Why It Matters
Patients with serious or life-threatening conditions often face limited treatment options, and waiting for new therapies can take years. The Breakthrough Therapy Designation (BTD) helps accelerate this process for drugs that show strong early evidence of being more effective than…